Development

AI moves from possibility to practice in drug discovery value chain

As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.

Feb. 17, 2026

Drug Delivery

The next phase of radioligand therapies is about execution

Jan. 6, 2026

Development

States competing for biomanufacturing investment turn to financial incentives

Dec. 4, 2025

Development

Plant-based biologics: From setbacks to reinvention

Nov. 13, 2025

Clinical Trials

Overseas cell processing may take a hit as FDA reviews trials

Sept. 22, 2025

eBook: Solid dose manufacturing investments on the rise

Aug. 25, 2025

Drug Approvals

Advancing preclinical research with virtual control groups

Dec. 5, 2024

Drug Approvals

Notable 2024 FDA decisions

July 31, 2024

Large Molecule

Pharma’s molecular glue garden

April 16, 2024

Development

AI moves from possibility to practice in drug discovery value chain

The next phase of radioligand therapies is about execution

States competing for biomanufacturing investment turn to financial incentives

Plant-based biologics: From setbacks to reinvention

Overseas cell processing may take a hit as FDA reviews trials

eBook: Solid dose manufacturing investments on the rise

Advancing preclinical research with virtual control groups

Notable 2024 FDA decisions

Pharma’s molecular glue garden

Looking for Something?